TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7643821
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ketoprofen lysine salt suppositories
Study: 7643821
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketoprofen lysine salt suppositories
Study: 7643821
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg ketoprofen lysine salt suppositories
Study: 7643821
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ketoprofen lysine salt suppositories
Study: 7643821
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ketoprofen lysine salt suppositories
Study: 2751841
Drug: Ketotifen 0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 0.35 mg every 12 hours
Study: 782977
Drug: Oral killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral killed typhoid vaccine (100.10^9 killed S. typhi)
Study: 782977
Drug: Oral killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral killed typhoid vaccine (300.10^9 killed S. typhi)
Study: 782977
Drug: Oral killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral killed typhoid vaccine (400.10^9 killed S. typhi)
Study: 31302768
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: IANB and buccal infiltration (BI) of 4% articaine
Study: 31302768
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: IANB + BI and intraseptal injection of articaine
Study: 29703998
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OXT) administration
Study: 29703998
Drug: Placebo (PLC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLC) administration
Study: 28370178
Drug: Curcuma (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuma (6 g containing 2% curcumin)
Study: 26438237
Drug: Short-term fasting
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term fasting (STF) 24 hours before and after chemotherapy
Study: 19808351
Drug: Serial B-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial B-type natriuretic peptide testing (at 3, 6, 9, and 12 hours then daily)
Study: 11435883
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (240 ml, 3 times daily for 7 days)
Study: 11435883
Drug: Control (tap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (tap water, 240 ml, 3 times daily for 7 days)
Study: 9682700
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with early worsening
Study: 9682700
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment initiation
Study: 28801967
Drug: Experimental retreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental retreatment with subcutaneous bortezomib plus dexamethasone (VD)
Study: 24345356
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual with smoking-cessation treatment (weekly individual smoking cessation counseling and extended-release bupropion 300 mg/d during weeks 1-10, nicotine inhaler and contingency management for smoking abstinence during weeks 4-10)
Study: 24345356
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual with smoking-cessation treatment
Study: 12492746
Drug: Forlax (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forlax (10 g)
Study: 12492746
Drug: Forlax (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forlax (20 g)
Study: 12492746
Drug: Transipeg (5.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transipeg (5.9 g)
Study: 12492746
Drug: Transipeg (11.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transipeg (11.8 g)
Study: 9337835
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of gas mixtures with varying fractional inspired oxygen concentration (FiO2) from 0.1 to 1.0
Study: 9337835
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of gas mixtures with FiO2 of 0.1
Study: 8449125
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins (vitamin A 30,000 IU/day, vitamin C 1 g/day, vitamin E 70 mg/day)
Study: 8449125
Drug: Lactulose (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (20 g/day)
Study: 2869676
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 to 160 mg 3 times a day)
Study: 2869676
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 to 120 mg 3 times a day)
Study: 29864732
Drug: Telephone-delivered mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered mindfulness-based cognitive therapy (MBCT-T)
Study: 18803955
Drug: Telmisartan 47.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 47.0 mg/d
Study: 18803955
Drug: Candesartan 8.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8.4 mg/d
Study: 18803955
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no change in drug regimen)
Study: 16169302
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg nicotine enema
Study: 16169302
Drug: Nicotine therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine therapy
Study: 11974560
Drug: CEE/MPA 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA 0.625 mg-5.0 mg daily for 13 treatment cycles (28 days each)
Study: 11974560
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg daily for 13 treatment cycles (28 days each)
Study: 10482696
Drug: Superselective intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Superselective intra-arterial chemotherapy
Study: 10482696
Drug: Systemic intravenous
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic intravenous chemotherapy
Study: 6163166
Drug: gamma-globulin/histamine complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma-globulin/histamine complex by subcutaneous injection
Study: 6163166
Drug: active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: active treatment (gamma-globulin/histamine complex)
Study: 31881879
Drug: High-energy dose
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy dose TUS combined with a rehabilitation program
Study: 11738336
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of levofloxacin 500 mg once daily
Study: 11738336
Drug: 7-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day course of levofloxacin 500 mg once daily
Study: 9463638
Drug: Losartan (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (selective AT1 receptor antagonist)
Study: 8505747
Drug: Acetard 300
Normalized name: lanreotide
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acetard 300 mg
Study: 8505747
Drug: Acetard 100
Normalized name: flecainide acetate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetard 100 mg
Study: 8505747
Drug: Platet 100
Normalized name: PLATELET GLYCOPROTEIN VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platet 100 mg
Study: 3691010
Drug: Two 5‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 5‐mg tablets (Treatment A)
Study: 3691010
Drug: One 10‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 10‐mg tablet (Treatment B)
Study: 3691010
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of a 1‐mg/mL suspension (Treatment C)
Study: 3691010
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of a 1‐mg/mL aqueous reference solution (Treatment D)
Study: 3691010
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between Treatment A and Treatment D
Study: 3691010
Drug: Bioequivalence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioequivalence of dosage forms
Study: 30955362
Drug: Pedometer worn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer worn on the hip with visible step count and daily recording
Study: 23926679
Drug: Spermatic cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spermatic cord seal-up injection (lidocaine, gentamicin or Amikacin, dexamethasone), qd or bid, for 2 courses of 5 days each, with an interval of 3 to 5 days.
Study: 23926679
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment (intravenous drip of penicillin, qd; intramuscular injection of Streptomycin, bid; oral SMZCo, bid, with initial dose doubled).
Study: 15387802
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of eccentric exercises and night splint
Study: 11212044
Drug: Remifentanil iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil iv followed by a continuous infusion of 0.25 to 0.50 microg x kg(‐1) x min(‐1)
Study: 9771298
Drug: Hydroxyzine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine (1 mg kg‐1)
Study: 28235621
Drug: Low-dose CAP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CAP (2 mg/d; L-CAP, n = 27)
Study: 28235621
Drug: High-dose CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CAP (4 mg/d; H-CAP, n = 22)
Study: 25963985
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g GSR‐PAS twice daily
Study: 25963985
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g GSR‐PAS once daily
Study: 23433101
Drug: Everolimus 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 1.5 mg with reduced-dose cyclosporine
Study: 23433101
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 3 g/day with standard-dose cyclosporine
Study: 21615449
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) treatment for 15 months
Study: 21615449
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) treatment in mice with EAE
Study: 19062230
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol and ipratropium with warmed humidified oxygen
Study: 19062230
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol and ipratropium with humidified oxygen at room temperature
Study: 19062230
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol with warmed humidified oxygen
Study: 19062230
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol with humidified oxygen at room temperature
Study: 29229305
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (50,000 IU weekly for 12-14 weeks)
Study: 28853392
Drug: Sertraline prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline prescribed in therapeutic doses for 12 months
Study: 28853392
Drug: High-intensity Cognitive
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity Cognitive Behavioural Therapy (CBT) delivered in 14 sessions
Study: 23571176
Drug: HPV‐16/18 AS04‐adjuvated
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV‐16/18 AS04‐adjuvated vaccine
Study: 18339153
Drug: 2 mg/ml
Normalized name: urea 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/ml of both morphine and ketamine (Ketamine group, n=26)
Study: 18339153
Drug: 2 mg/ml
Normalized name: urea 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/ml of morphine (Control group, n=30)
Study: 16362788
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy (68-MeV protons)
Study: 7559293
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 10 mg bid
Study: 7559293
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 20 mg bid
Study: 419163
Drug: Psychotropic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic drugs (20 different types)
Study: 27209164
Drug: Erlotinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib plus Bevacizumab (150 mg daily of erlotinib and 15 mg/kg of bevacizumab intravenously on day 1 of every 21-day cycle)
Study: 24039147
Drug: Instant pure
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant pure soluble coffee (three increasing doses)
Study: 20619460
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin analog (PGA) in 1 eye
Study: 12809961
Drug: Tramadol 37.5
Normalized name: ACETAMINOPHEN 325MG/TRAMADOL 37.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 37.5 mg/APAP 325 mg combination tablets
Study: 8866038
Drug: Zenith Laboratories
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zenith Laboratories nicardipine (30 mg) under fasted conditions
Study: 31727154
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mDCs and pDCs vaccination
Study: 31727154
Drug: All DC
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All DC vaccines
Study: 7588499
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) replacement therapy for 3 months
Study: 7955441
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) replacement therapy
Study: 30986513
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (scaling and root planing) during the first 6 months
Study: 20537140
Drug: Self-reported medication
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported medication side effects
Study: 20537140
Drug: Risk factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factors for medication side effects
Study: 20537140
Drug: Liver problems
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver problems and doctor's awareness of medications
Study: 15860043
Drug: Tenecteplase (weight-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (weight-adjusted dose)
Study: 12375548
Drug: Chlorhexidine 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine 0.2% vaginal flushings (140 ml every 6 hours until delivery)
Study: 12375548
Drug: Ampicillin 2
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 2 g intravenously (every 6 hours until delivery)
Study: 1724166
Drug: MK886 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK886 (oral leukotriene biosynthesis inhibitor)
Study: 29549104
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg of 0.1% E2 gel per day
Study: 17766739
Drug: IV NTG
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV NTG (initial dose of 0.05 microg.kg(‐1).min(‐1), followed by 0.1 microg.kg(‐1).min(‐1))
Study: 15240604
Drug: Withdrawal from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal from T(4) therapy
Study: 15240604
Drug: No transient
Approvals — FDA: no, EMA: no, PMDA: no
Description: No transient therapy with T(3)
Study: 12097994
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream (Elidel)
Study: 7936174
Drug: Gadodiamide injection
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadodiamide injection at 0.1 mmol/kg body weight
Study: 7936174
Drug: Gadodiamide injection
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadodiamide injection at 0.3 mmol/kg body weight
Study: 7936174
Drug: Gadodiamide injection
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadodiamide injection (both doses)
Study: 3337574
Drug: Lotion soap
Normalized name: Medicated Lotion Soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion soap (Safe 'N Sure)
Study: 1493935
Drug: Low-dose AraC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose AraC (2 x 10 mg/m2 subcutaneously days 1‐14) plus GM-CSF (2 x 150 micrograms protein/day subcutaneously)
Study: 835531
Drug: Boric acid-sodium
Normalized name: Boric Acid
DrugBank: Boric acid (DB11326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Boric acid-sodium borate solution
Study: 31733045
Drug: Podiatry intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podiatry intervention (3 visits, foot orthoses, exercise, manual therapy, advice)
Study: 31733045
Drug: Usual GP
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual GP care (1 visit, medication advice/prescription, same advice as podiatry group)
Study: 30312162
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with standard-of-care pain treatment
Study: 26552423
Drug: Standard-of-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment only
Study: 24217275
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care treatment (CG)
Study: 10445535
Drug: Serial IgG
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial IgG antibody determinations
Study: 10445535
Drug: Parallel IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parallel IgG antibody determinations
Study: 465432
Drug: Iron fortification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron fortification of food providing 10 mg elemental Fe/child per day
Study: 465432
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (5 mg) mixed in one meal
Study: 465432
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (3.3 mg) given with each of three meals over 2 days
Study: 465432
Drug: Ferrous ascorbate
Normalized name: Ferrous ascorbate
DrugBank: Ferrous ascorbate (DB14490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous ascorbate (test dose)
Study: 29096672
Drug: Yoga (90-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga (90-min session weekly for 8 weeks)
Study: 29096672
Drug: Stretching and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching and resistance exercises (60-min session weekly for 8 weeks)
Study: 19772596
Drug: Structured weekly
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured weekly SMS messaging
Study: 17963859
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pills (OCs) initiation
Study: 2617244
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg i.v.
Study: 22284315
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with tramadol (1.0 mg/kg loading dose, 10 mg metoclopramide, 0.3 mg/kg/mL every 5 minutes)
Study: 22284315
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with remifentanil (placebo 100 mL 0.9% normal saline, 0.4 μg/kg/mL every two minutes)
Study: 16285948
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (17 to 23 mg/kg body weight per day)
Study: 11929950
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy with sequentially added progestins (HRTsp)
Study: 11929950
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy with continuously added progestins (HRTcp)
Study: 11929950
Drug: Low-potency estrogens
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-potency estrogens (oral)
Study: 7638806
Drug: All modes
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All modes of inhalation studied
Study: 2572036
Drug: Broxaterol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (oral route, total dose 1.675 mg)
Study: 2572036
Drug: Broxaterol (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (inhaled route, total dose 1.5 mg)